

ZIOPHARM Oncology, Inc. Investor Relations Department One First Ave., Parris Building, # 34 Navy Yard Plaza Boston, MA 02199 United States

Visit IR website ☐ Sign-up for Email alerts ☐

NASDAQ: ZIOP	
Last Trade:	6.03
Trade Time:	2:32 PM ET Jul 25, 2017
Change:	0.16 1 (+2.726%)
Day Range	5.79 - 6.09
52-Week Range	4.55 - 7.88
Volume	808,074


Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

Company Profile

ZIOPHARM Oncology, Inc. is a biopharmaceutical company that is seeking to develop and commercialize a diverse portfolio of treatments for people with cancer and graft-versus-host-disease. Our focus is on the development of cell and viral-therapies using a suite of technologies that employing novel gene expression, control and cell technologies to deliver safe, effective and scalable therapies.

... (more)

Stock Performance



Press Releases [View all]

Jul 24, 2017

ZIOPHARM Oncology to Host Second-Quarter 2017 Financial Results and Corporate Update Conference Call on July 31, 2017 at 4:30 p.m. ET

Jun 28, 2017

ZIOPHARM Oncology Announces Initiation of Stereotactic Treatment Cohort in Phase 1 Study of Ad-RTS-hIL-12 + Veledimex in Recurrent Glioblastoma

Jun 5, 2017

ZIOPHARM Oncology Announces Positive
Updated Results of Ad-RTS-hIL-12 +
Veledimex in Recurrent Glioblastoma at the
2017 ASCO Annual Meeting

Jun 2, 2017

ZIOPHARM to Present at the Jefferies 2017 Global Healthcare Conference

May 17, 2017

ZIOPHARM Oncology Announces Results of Ad-RTS-hIL-12 + Veledimex in Recurrent Glioblastoma to be Presented at the 2017 ASCO Annual Meeting

Upcoming Events [View all]

Jul 31, 2017 4:30 PM ET

Ziopharm Second Quarter 2017 Financial
Results Conference Call

Financials [View all]

Feb 16, 2017 Annual Report (10-K)

Apr 28, 2017 Proxy Statement (DEF 14A)

May 1, 2017
Quarterly Report (10-Q)

Nov 9, 2016

Quarterly Report (10-Q)

Aug 9, 2016

Quarterly Report (10-Q)